Now approved for first-line maintenance treatment regardless of biomarker status1
Zejula is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.1*
Proven efficacy regardless of biomarker status
A safety and tolerability profile consistent with previous clinical trial experience1-3
88% of women in the overall population remained on Zejula therapy without discontinuations due to AEs1,2
Side effects can be managed with dose interruption and modification.
- AEs led to dose interruptions and reduction in 80% of patients, most frequently from thrombocytopenia (56%), anaemia (33%), and neutropenia (20%).
Individualised Zejula dosing reduced haematological AEs and maintained PFS vs a fixed starting dose1, 4-6
- For patients weighing <77 kg OR with a platelet count <150,000/ uL, the recommended dose is 200mg taken orally once daily.1
- For patients weighing ≥77 kg AND a platelet count ≥150,000/uL, the recommended dose is 300 mg taken orally once daily.1
PRIMA- Impact of individualised dosing on adverse events5
Convenient, once-daily oral dosing1
© 2020 GSK Group of Companies or its licensor.
Trademarks are the property of their respective owners.
February 2021 | PM-GB-NRP-WCNT-200008